Jong Geun Jeong

Jong Geun Jeong is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of novel antibodies. With a total of 3 patents to his name, his work focuses on innovative solutions for medical applications.

Latest Patents

One of Jong Geun Jeong's latest patents is a dual-target antibody that specifically targets VEGFR-2 and DLL4. This invention includes a gene encoding the antibody, a recombinant expression vector, and host cells transformed with this vector. The pharmaceutical composition derived from this dual-target antibody has potential applications in treating various diseases. Another notable patent is for a human antibody specific to c-Met, which includes a preparation method. This fully human antibody exhibits high affinity and specificity to c-Met, making it a valuable tool for controlling c-Met activity in vivo.

Career Highlights

Jong Geun Jeong is currently employed at Pharmabcine Inc., where he continues to advance his research in antibody development. His work has garnered attention for its potential impact on therapeutic strategies in oncology and other medical fields.

Collaborations

Jong Geun Jeong collaborates with notable colleagues such as Jin San Yoo and Weon Sup Lee. Their combined expertise contributes to the innovative research environment at Pharmabcine Inc.

Conclusion

Jong Geun Jeong is a distinguished inventor whose work in antibody development is paving the way for new medical treatments. His contributions to biotechnology highlight the importance of innovation in addressing complex health challenges.

This text is generated by artificial intelligence and may not be accurate.